Micrometastases or XXXX cells and the outcome of @entity0 .

@entity5 @entity1 @entity0
BACKGROUND: The association of @entity5 cells and micrometastases in regional lymph nodes with the clinical outcome of @entity0 is unclear. METHODS: We identified all @entity1 in The Netherlands who underwent a sentinel-node biopsy for @entity0 before 2006 and had @entity0 with favorable @entity5 characteristics and @entity5 cells or micrometastases in the regional lymph nodes. @entity1 with node-negative disease were randomly selected from the years 2000 and 2001. The primary end point was disease-free survival. RESULTS: We identified 856 @entity1 with node-negative disease who had not received systemic adjuvant therapy (the node-negative, no-adjuvant-therapy cohort), 856 @entity1 with @entity5 cells or micrometastases who had not received systemic adjuvant therapy (the node-positive, no-adjuvant-therapy cohort), and 995 @entity1 with @entity5 cells or micrometastases who had received such treatment (the node-positive, adjuvant-therapy cohort). The median follow-up was 5.1 years. The adjusted hazard ratio for disease events among @entity1 with @entity5 cells who did not receive systemic therapy, as compared with @entity1 with node-negative disease, was 1.50 (95% confidence interval [CI], 1.15 to 1.94); among @entity1 with micrometastases, the adjusted hazard ratio was 1.56 (95% CI, 1.15 to 2.13). Among @entity1 with @entity5 cells or micrometastases, the adjusted hazard ratio was 0.57 (95% CI, 0.45 to 0.73) in the node-positive, adjuvant-therapy cohort, as compared with the node-positive, no-adjuvant-therapy cohort. CONCLUSIONS: @entity5 cells or micrometastases in regional lymph nodes were associated with a reduced 5-year rate of disease-free survival among @entity1 with favorable @entity0 who did not receive adjuvant therapy. In @entity1 with @entity5 cells or micrometastases who received adjuvant therapy, disease-free survival was improved.
